Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
Rhea-AI Summary
Immunovant announced that data from their Phase 2a trial of batoclimab in Graves' disease will be presented at the 2024 American Thyroid Association Annual Meeting in Chicago. The late-breaking oral presentation will showcase new data on both thyroid-specific and extrathyroidal manifestations of Graves' disease. The presentation titled 'Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves' Thyroidal and Extrathyroidal Disease: a Proof-of-concept Study' will be delivered by Dr. George Kahaly on November 1, 2024.
Positive
- Phase 2a trial data selected for late-breaking presentation at major medical conference
Negative
- None.
News Market Reaction – IMVT
On the day this news was published, IMVT declined 0.23%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves’ disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting both thyroid-specific and extrathyroidal manifestations of Graves' disease will be presented.
Late-Breaking Oral Presentation Details:
| Title: | Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves’ Thyroidal and Extrathyroidal Disease: a Proof-of-concept Study |
| Presentation: | #0020 |
| Session: | #5 – Autoimmune Thyroid Disease |
| Date and Time: | Friday, November 1, 2024, 4:05pm – 5:05pm ET |
| Presenter: | George Kahaly, MD, PhD |
About Graves’ disease
Graves’ disease is an autoimmune disorder associated with the overproduction of thyroid hormones and is the most common cause of hyperthyroidism. Although Graves’ disease can affect any age group or gender, it occurs often in women younger than 40 years of age. In Graves’ disease, harmful IgG autoantibodies bind to and activate the thyroid-stimulating hormone receptor present on the thyroid gland, stimulating excess thyroid hormone production. Existing treatments, which include antithyroid drugs, radioactive iodine, and thyroid surgery, are aimed at reducing thyroid hormone levels to lessen the severity of symptoms. These treatments have remained largely unchanged for the past 70 years.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contact:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
info@immunovant.com
Source: Immunovant, Inc.
FAQ
When will Immunovant (IMVT) present its Phase 2a Graves' disease trial data?
What is the focus of Immunovant's (IMVT) Phase 2a trial presentation?
Who will present Immunovant's (IMVT) Graves' disease trial data at ATA 2024?
